Presentation is loading. Please wait.

Presentation is loading. Please wait.

Branko N Huisa M.D. Assistant Professor of Neurology UNM Stroke Center.

Similar presentations

Presentation on theme: "Branko N Huisa M.D. Assistant Professor of Neurology UNM Stroke Center."— Presentation transcript:

1 Branko N Huisa M.D. Assistant Professor of Neurology UNM Stroke Center


3 CHANGABLE Blood pressure Diabetes Mellitus Hyperlipidemia Atrial fibrillation Nicotine Drug abuse Life style NOT CHANGABLE Age Sex Race History of TIA or stroke Family history of TIA/stroke

4 Antihypertensive medication. Diabetic control. Tobacco cessation. Antiplatelets. Anticoagulants. Statins. Diet. Exercise. Education.


6 *Based on NHANES 19992000 data. Hypertension is defined as blood pressure 140/90 mmHg or antihypertensive treatment. Fields et al. Hypertension. 2004:44;398-404.



9 Lancet 1990

10 BP reductions between groups with risks of major vascular outcomes and death Lancet 2003 SBP difference between randomized groups (mm Hg)

11 Lancet 2002; 360: 1903–13.

12 Reduce 10mmHg diastolic BP Reduce 20mmHg systolic BP Lancet 2002; 360: 1903–13.

13 No severe hypertension. NNT=118 (DBP 90-110 mm Hg). Moderate hypertension. NNT =52 (DBP at or below 115 mm Hg) Severe hypertension. NNT=29 (DBP above 115 mm Hg) Secondary prevention: NNT=110 (for patients with initial BP <160/90 mmHg and reduction by 12/5 mm Hg) PROGRESS Lancet 2001

14 Aspirin Mechanism: (inhibits PG synthesis) Inhibits PGH synthase pre- systemically. Covalently acetylates Cyclo-oxygenase (irr.) Inhibits platelet function by 1 hour. Lasts entire platelet lifetime (~10d) Efficacy is not in question. Controversy: o Dosage o Aspirin resistance Aspirin

15 00.5 1.0 1.5 2.0 500-1500 mg 34 19 160-325 mg 19 26 75-150 mg 12 32 <75 mg 3 13 Any aspirin 65 23 Antiplatelet BetterAntiplatelet Worse Aspirin Dose No. of Trials OR (%) Odds Ratio *Vascular events included nonfatal MI, nonfatal stroke, and death from vascular causes. Treatment effect P<.0001. Antithrombotic Trialists Collaboration. BMJ. 2002;324:71-86.

16 CAST & IST: Metaanalysis ~40,000 pts. ~99% of evidence from randomized trials. Reduction of 9/1000 overall risk of further cva/ death in hospital. Reduction of 7/1000 ischemic cva. (p<0.000001) * Starting ASA early reduces risk of recurrent cva. ______________ Chen. Stroke 2000;31:1240. Aspirin within 24hrs after CVA

17 CAPRIE : (Clopidogrel vs ASA) Clopidogrel (75mg) ASA (325mg) 19,185 pts. c h/o CVA/ MI/ PVD Incidence5.83% (ASA) 5.32% (Clopidogrel) * 8.7% (p=0.05) Relative RR. ______________ CAPRIE Clopidogrel

18 Cumulative Event Rate (Myocardial Infarction, Ischemic Stroke or Vascular Death) Months of follow-up 8.7% * Overall relative Risk Reduction 0 4 8 12 16 0 369121518212427303336 Cumulative event rate (%) p=0.043 Clopidogrel (n=9,599) 1. CAPRIE Steering Committee. Lancet 1996; 348: 1329–1339. 2. Antiplatelet Trialists' Collaboration. BMJ 2002; 324: 71–86. *Intention to treat analysis ASA (n=9,586) CAPRIE: Clopidogrel

19 ______________ CAPRIE Overall safety = asa. Sl. more effective in reducing end- points (cva/mi/vasc.d) all pt result driven by subset of PVD pts Results: CAPRIE: Clopidogrel

20 Bhatt D et al. N Engl J Med 2006;354:1706-1717 Diener et al. Lancet 2004;364:331-337 CHARISMAMATCH

21 ESPRIT Study Group. Lancet 2006;367:1665-1673. 30–325mg Aspirin and 200 Dipyridamole BID versus 30-325mg Aspirin Alone (ESPRIT) Dipyridamole n=2739 all with stroke or TIA Dipyridamole stopped 470 ASA alone stopped 184 1% event reduction per year

22 ESPRIT is an un-blinded trial Patients and physicians were aware of applied medication with potential bias 400 mg daily dipyridamole with different formulations extended (modified) release immediate release Aspirin dose from 30 to 325 mg De Schryver et al. Cerebrovasc Dis. 2000;10:147-50.






28 There is no evidence to conclude superiority of one antiplatelet therapy over other. Antiplatelet therapy should be used for secondary stroke prevention. NNT 100 AHA Guidelines Stroke 2011



31 Tight Glucose control Maybe Tight BP control YES! UKPDS. BMJ 1998


33 Lower LDL cholesterol. Modest increase of HDL cholesterol. Improve endothelial dysfunction. Increase NO. Neuroprotective effect. Antiinflammatory properties Antithrombotic effects Immunomodulation

34 NEJM 2006

35 Huisa et al 2010

36 Based on SPARCL: NNT=46 in 5 years High dose therapy with a reduction of LDL>50% (NNT15 in 5 years)


38 16 trials on stroke prevention in AF (n=9874) Warfarin reduced stroke by 62% absolute reduction 2.7% for primary and 8.4% for secondary prevention Aspirin reduced stroke by 22% absolute 1.5 and 2.5% Hart RG, et al. Stroke 1999.


40 p=0.34 p<0.001 NEJM 2009



43 Schloten et al. Europace 2005

44 The ACTIVE Investigators. N Engl J Med 2009;10.1056/NEJMoa0901301 Patients who have AF but cannot take warfarin n=7,554 3.6 years All received ASA Major vascular events: clopidogrel 6.8% / year, placebo 7.6% / year) Stroke: clopidogrel 2.4% per year, placebo 3.3% per year Major bleeding: clopidogrel 2.0% per year, placebo 1.3% per year

45 Cumulative Hazard Rates for the Primary Efficacy and Safety Outcomes,According to Treatment Group N Engl J Med 2011


47 Mediterranean Low carbohydrate Low Fat EAT LESS LIVE LONGER!

48 N :322, BMI:31


50 Dietary Intervention to Reverse Carotid Atherosclerosis Shai et al. Circulation 2010

51 Morgestein et al. Ann Neurol 2009 RR(95% CI): 1.13 (1.02–1.25)

52 Adult human body requirements: < 5.8 g of salt mg (AHA 2010) Ideal for stroke prevention < 4 g of salt Average USA consumption 10.4 g of salt per mg (CDC 2006)

53 Projected Annual Reductions in Cardiovascular Events Given a Dietary Salt Reduction of 3 g per Day. NEJM2010


55 Eat more fresh foods, especially fruits and vegetables Purchase processed foods with low salt claims on labels, or brands with the lowest % of daily sodium intake on the food label. Avoid heavily salted foods (pickled foods, olives, salted crackers or snacks, process meats, etc). Rinse canned foods with water before eating Use less salt in home cooking and no added salt at the table.


57 Antihypertensive medication. Diet. Statins. Antiplatelets. Exercise and body weight. Tobacco cessation. Diabetic control. Anticoagulants for A-fib

58 Hackam, D. G. et al. Stroke 2007;38:1881-1885 Antithrombotics+high dose statins +Diet&exercise+Tight BP control


60 Percentage of respondents unable to name correctly 1 warning sign or risk factor. Pancioli, A. M. et al. JAMA 1998;279:1288-1292 Copyright restrictions may apply.

61 Stroke 2011


Download ppt "Branko N Huisa M.D. Assistant Professor of Neurology UNM Stroke Center."

Similar presentations

Ads by Google